Blood Testing Market (By Test Type: Glucose Testing, A1C Testing, Direct LDL Testing, Lipid Panel Testing, Prostate-specific Antigen Testing, COVID-19 Testing, BUN Testing, Vitamin D Testing, Thyroid-stimulating Hormone (TSH), Serum Nicotine/Cotinine, High-sensitivity CRP Testing, Testosterone Testing, ALT Testing, Cortisol Testing, Creatinine Testing, AST Testing, Other Blood Tests, and Others.) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global blood testing market size was USD 98.52 billion in 2023, accounted for USD 105.65 billion in 2024 and is expected to reach around USD 198.19 billion by 2033, expanding at a CAGR of 7.24% from 2024 to 2033. The rising number of diagnostic centers worldwide is driving the growth of the blood testing market.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. blood testing market size surpassed USD 30.34 billion in 2023 and is projected to attain around USD 62.18 billion by 2033, poised to grow at a CAGR of 7.43% from 2024 to 2033.
North America holds the largest blood testing market share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth of this region is mainly driven by the rising technological developments in the healthcare industry. Also, the increasing prevalence of chronic diseases such as Cancer, Cardiovascular diseases, and others has increased the demand for blood testing for proper diagnosis and getting cured, thereby driving the market growth. According to a study by Cancer.net, around 14% of lung cancer patients suffer from Small Cell Lung Cancer (SCLC) in the U.S.. It is also estimated that approximately 238,440 adults will be suffering from lung cancer in 2023 in the U.S.A.
Moreover, growing government investments in the development of healthcare sectors in countries such as the U.S.A., Canada, Mexico, and some others have also boosted the growth of the blood testing market. For instance, in August 2022, the U.S. Department of Health and Human Services (HHS) announced an investment of 60 million USD to increase the healthcare workforce along with providing good quality healthcare in rural areas of the U.S.A.. Additionally, the increased prevalence of rare diseases in North America has increased the demand for blood testing, thereby driving the market growth. According to the National Institutes of Health (NIH), around 7000 people in the U.S. suffer from rare diseases. It also stated that one in every ten people across the U.S. suffered from rare diseases. Furthermore, the presence of healthcare companies such as Abbott, Biorad Laboratories, Thermo Fisher Scientific, Danaher Corporation, and others boosts the market growth.
Asia Pacific is estimated to be the fastest-growing region during the forecast period. The growth of this region is mainly driven by the scientific advancements in the healthcare sector in countries such as India, Israel, China, Japan, and some others. Also, the rising interest from the public and private sectors for development & research related to blood testing methodologies has also boosted the market growth. Moreover, rising government initiatives in countries such as India and Japan to develop the medical sectors have fostered market growth.
Market Overview
The blood testing market is a very important industry in the healthcare domain. This industry has gained prominence due to the prevalence of various diseases worldwide. A blood test is a laboratory diagnosis done by extracting a blood sample from a person through different parts of the body. This testing methodology is the first step to diagnosing any mild or serious disease. There are several types of blood tests, including glucose testing, A1C testing, direct LDL testing, lipid panel testing, prostate-specific antigen testing, and others.
Report Coverage | Details |
Market Size in 2023 | USD 98.52 Billion |
Market Size in 2024 | USD 105.65 Billion |
Market Size by 2033 | USD 198.19 Billion |
Market Growth Rate from 2024 to 2033 | CAGR of 7.24% |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Rising cases of Alzheimer’s disease across the world
The prevalence of Alzheimer’s disease has increased rapidly due to several lifestyle factors, such as smoking, overdrinking, unhealthy diets, and others. This disease is mainly associated with memory loss along with other mental dysfunctionalities. According to the Alzheimer’s Association, around 7 million people in America suffer from Alzheimer’s disease. Thus, with the rising cases of Alzheimer’s disease, the demand for blood testing also increases, thereby driving the growth of the blood testing market. Moreover, several healthcare companies such as Abbott, Biorad, Quanterix, and others have started developing advanced blood testing methods for faster diagnosis of Alzheimer’s disease, which, in turn, boosts the market growth.
Several risks are associated with testing and wrong results
There are several problems associated with blood testing. Firstly, there are various side effects such as fever, headache, digestion issues, fainting, allergic reactions, appetite loss, and some others. Secondly, the problems associated with the storage and transportation of blood samples can result in false reports. Thus, several side effects and wrong results related to blood testing are expected to restrain the market growth to some extent.
Integration of modern technologies for blood testing
The blood testing industry has grown drastically with rapid developments in the healthcare sector. Nowadays, doctors prescribe different types of blood testing for the detection of very mild and serious diseases. Also, the advancement in modern technologies such as AI, Blockchain, and Machine Learning (ML) has allowed healthcare companies to integrate these technologies into their system to get accurate results of blood tests quickly.
The glucose testing segment held the largest share in 2023. The growth of this segment is driven by the rising cases of diabetes patients across the world. Also, the rise in the number of diagnostics centers, along with scientific developments associated with glucose testing, has driven the growth of the blood testing market. Moreover, healthcare companies are continuously engaged in research and development to develop new blood testing systems to get accurate glucose testing results, thereby driving market growth. Additionally, the ongoing trend of over-the-counter continuous glucose monitoring systems (CGM) among people across the world is driving the growth of the blood testing market. Furthermore, the growing trend of AI-based glucose monitoring systems across the world has boosted market growth.
The A1C segment is expected to show significant growth during the forecast period. The growth of this segment can be attributed to the growing number of patients suffering from anemia across the world. Also, the growing number of surgeries across the world has increased the demand for A1C testing, as surgeries are associated with blood loss, thereby driving the growth of the blood testing market. Moreover, healthcare companies are developing and launching several portable A1C testing devices across the world, which, in turn, drive the growth of the blood testing market.
Recent Developments
Segments Covered in the Report
By Test Type
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Blood Testing Market
5.1. COVID-19 Landscape: Blood Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Blood Testing Market, By Test Type
8.1. Blood Testing Market, by Test Type, 2024-2033
8.1.1. Glucose Testing
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. A1C Testing
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Direct LDL Testing
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Lipid Panel Testing
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Prostate-specific Antigen Testing
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. COVID-19 Testing
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. BUN Testing
8.1.7.1. Market Revenue and Forecast (2021-2033)
8.1.8. Vitamin D Testing
8.1.8.1. Market Revenue and Forecast (2021-2033)
8.1.9. Thyroid-stimulating Hormone (TSH)
8.1.9.1. Market Revenue and Forecast (2021-2033)
8.1.10. Serum Nicotine/Cotinine
8.1.10.1. Market Revenue and Forecast (2021-2033)
8.1.11. High-sensitivity CRP Testing
8.1.11.1. Market Revenue and Forecast (2021-2033)
8.1.12. Testosterone Testing
8.1.12.1. Market Revenue and Forecast (2021-2033)
8.1.13. ALT Testing
8.1.13.1. Market Revenue and Forecast (2021-2033)
8.1.14. Cortisol Testing
8.1.14.1. Market Revenue and Forecast (2021-2033)
8.1.15. Creatinine Testing
8.1.15.1. Market Revenue and Forecast (2021-2033)
8.1.16. AST Testing
8.1.16.1. Market Revenue and Forecast (2021-2033)
8.1.17. Other Blood Tests
8.1.17.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Blood Testing Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.1.2. U.S.
9.1.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.2.3. Germany
9.2.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.2.4. France
9.2.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.2.5. Rest of Europe
9.2.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
Chapter 10. Company Profiles
10.1. Abbott
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. F. Hoffmann-La Roche AG
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Bio-Rad Laboratories, Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. BioMerieux SA
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Quest Diagnostics
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Biomerica, Inc.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Becton, Dickinson and Company
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Siemens Healthineers
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Danaher Corporation
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Trinity Biotech Plc
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client